Clinical Study
Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
Table 1
Patient characteristics at baseline.
| | Patient ID | Gender/Age (years)/Diagnosis | Body mass index () | Small bowel (cm) | Colon-in-cont. (%) | Time since last surgery (years) | Wet weight intake (kg/d) | Fecal wet weight excretion (kg/d) | Parenteral fluid (L/d) | Diet energy intake (MJ/d) | Fecal energy excretion (MJ/d) | Patenteral energy (MJ/d) | Duration of HPN (years) | Time on GLP-2 (days of ) |
| | HRM | F/47/CD | 21.3 | 150 | 0 | 2.5 | 5.2 | 3.7 | 1.0 | 13.5 | 7.1 | 0.8 | 2.5 | | | LM | M/27/CD | 21.0 | 70 | 75 | 2.5 | 3.9 | 2.3 | 2.3 | 11.8 | 6.0 | 6.4 | 2.5 | | | OB | M/49/CD | 25.5 | 150 | 0 | 11.6 | 3.1 | 1.3 | 0.5 | 13.2 | 4.6 | 0.0 | 11.6 | Abd. Pain | | GL | M/53/CD | 17.3 | 180 | 0 | 20.6 | 3.2 | 1.6 | no | 16.8 | 4.4 | no | no | | | JP | M/24/CD | 20.4 | 130 | 100 | 2.3 | 3.1 | 0.7 | 1.8 | 16.4 | 4.6 | 4.5 | 2.3 | Abd. Pain | | EFP | F/55/CD | 17.5 | 50 | 0 | 0.5 | 2.2 | 4.9 | 3.1 | 8.0 | 7.1 | 5.5 | 1.7 | unrel. Feedback | | JE | M/44/UC compl. | 27.2 | 200 | 0 | 1.6 | 5.9 | 3.9 | no | 13.8 | 5.5 | no | no | | | JHJ | M/55/UC compl. | 22.2 | 200 | 0 | 2.3 | 4.6 | 1.9 | 1.3 | 17.8 | 2.8 | 0.4 | 2.3 | | | UDJ | F/50/UC compl | 25.8 | 150 | 0 | 0.9 | 2.8 | 2.2 | 2.9 | 8.8 | 2.2 | 2.7 | 2.9 | | | JV | M/67/CD | 22.6 | 180 | 0 | 12.1 | 8.7 | 7.1 | no | 28.2 | 18.1 | no | no | | | FVL | M/59/CD | 20.1 | 290 | 0 | 5.8 | 3.1 | 1.2 | no | 7.8 | 1.3 | no | no | |
|
|
Mmale, Ffemale, CDCrohns disease, UC compl. Ulcerative colitis complications, Abd. Pain Abdominal pain, Unrel. Feedback Unreliable feedback.
|
